- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
Patent holdings for IPC class A61K 31/444
Total number of patents in this class: 5081
10-year publication summary
355
|
392
|
430
|
447
|
427
|
462
|
503
|
441
|
359
|
110
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Takeda Pharmaceutical Company Limited | 2961 |
114 |
Novartis AG | 11238 |
110 |
Merck Sharp & Dohme LLC | 3689 |
83 |
Daiichi Sankyo Company, Limited | 1829 |
75 |
Bristol-myers Squibb Company | 5080 |
64 |
Boehringer Ingelheim International GmbH | 4629 |
60 |
F. Hoffmann-La Roche AG | 7958 |
56 |
Santen Pharmaceutical Co., Ltd. | 649 |
54 |
Gilead Sciences, Inc. | 1879 |
53 |
AstraZeneca AB | 3042 |
49 |
Janssen Pharmaceutica N.V. | 3839 |
45 |
Pfizer Inc. | 3322 |
42 |
Vertex Pharmaceuticals Incorporated | 1581 |
38 |
Merck Sharp & Dohme Corp. | 2247 |
36 |
Epizyme, Inc. | 383 |
36 |
Amgen Inc. | 3779 |
35 |
Hoffmann-La Roche Inc. | 3060 |
32 |
Genentech, Inc. | 3742 |
32 |
Dana-Farber Cancer Institute, Inc. | 2455 |
32 |
Eisai R&D Management Co., Ltd. | 1304 |
30 |
Other owners | 4005 |